Small biotech drugs get permanent Medicare price exemption—patients pay more

What it does

This bill exempts drugs made by small biotech companies from Medicare's drug price negotiation program, starting in 2029. A company qualifies if it has 5 or fewer drugs on the market, invests a rising percentage of revenue in R&D (30–70% depending on drug count), and is not foreign-owned. Once acquired by a larger company, the exemption ends.

Why we flagged it

The bill's operative mechanism is a carve-out from Medicare price negotiation for a defined class of drug manufacturers. It is not a subsidy or direct payment; it is a restraint on government's negotiating power, which leaves pricing authority with the manufacturer.

What the text implies

• The R&D investment threshold is self-reported and verified only through annual application; no independent audit mechanism is specified, creating potential for misclassification.
• A small biotech can qualify with just one drug if it invests 30% of revenue in R&D, meaning a single blockbuster drug could fund the exemption indefinitely.
• The exemption survives acquisition only if the acquirer also meets the R&D-intensive definition; this may incentivize acquisitions by other small biotechs rather than large pharma, fragmenting the market.
• No sunset date or periodic review is specified; the exemption is permanent once a drug qualifies, even if the company's R&D spending later drops below the threshold.
• The bill does not address whether drugs already approved and priced before 2029 can retroactively claim exemption, creating potential ambiguity in implementation.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary people and Medicare pay higher drug prices for a broad category of medications (any drug from a small biotech firm meeting the R&D threshold), while manufacturers retain full pricing discretion. The exemption is permanent and applies to all qualifying drugs, not a time-limited incentive.

Who stands to gain

• small biotech manufacturers (5 or fewer qualifying drugs)
• biotech companies with high R&D spending ratios

Named in the bill

Medicare, Social Security Act Section 1192, small biotech manufacturers, qualifying single source drugs, Secretary of Health and Human Services, covered nations (as defined in 10 U.S.C. § 4872(f))

Where it stands

1 cosponsor: 1 Republicans.

• Jun 3, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jun 3, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 5 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,970,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

Bill Cassidy, the sponsor, reported $1,329,254 in PAC receipts in the 2026 cycle.

• Acadia Pharmaceuticals — $1,290,000 on 2 filings
• Exelixis Inc. — $560,000 on 1 filing
• Exelixis, Inc. — $120,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.